This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
ChemoCentryx Past Earnings Performance
Past criteria checks 0/6
Key information
-47.2%
Earnings growth rate
-40.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -9.5% |
| Return on equity | -56.3% |
| Net Margin | -357.0% |
| Last Earnings Update | 30 Jun 2022 |
Recent past performance updates
Recent updates
ChemoCentryx shareholders approve $4.7B merger with Amgen
Oct 18ChemoCentryx GAAP EPS of -$0.44 misses by $0.03, revenue of $11.76M misses by $9.89M
Aug 09ChemoCentryx: Revisiting The Investment Case
Jun 21ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?
Jun 06
ChemoCentryx: Good Post-Approval Performance, But Needs More Time
Mar 03ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?
Feb 11Analysts Are Betting On ChemoCentryx, Inc. (NASDAQ:CCXI) With A Big Upgrade This Week
Jan 21Checking In On ChemoCentryx
Dec 15Is ChemoCentryx (NASDAQ:CCXI) Using Debt In A Risky Way?
Oct 09ChemoCentryx: Make Or Break PDUFA Date For Avacopan May Not Go The Company's Way
Sep 29ChemoCentryx And Avacopan In ANCA-Associated Vasculitis: Making Amends
Aug 24Time To Worry? Analysts Just Downgraded Their ChemoCentryx, Inc. (NASDAQ:CCXI) Outlook
Aug 11ChemoCentryx: CRL Less Likely
Jul 25ChemoCentryx, Inc.'s (NASDAQ:CCXI) Intrinsic Value Is Potentially 34% Above Its Share Price
Jul 11ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Jun 15ChemoCentryx reports avacopan in ANCA vasculitis at ERA-EDTA congress
Jun 08ChemoCentryx: CRL Likely
May 09ChemoCentryx downgraded on narrow Adcom backing, Tilray jumps on double upgrade; in today’s analyst action
May 07Chemocentryx shares plunge 47% as FDA report identifies concerns with vasculitis candidate
May 04When Will ChemoCentryx, Inc. (NASDAQ:CCXI) Become Profitable?
Mar 03ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Feb 04
ChemoCentryx: Great Drug, Good Prospects, Uncomfortable Stock Price
Jan 14Have ChemoCentryx, Inc. (NASDAQ:CCXI) Insiders Been Selling Their Stock?
Dec 31Analyst Forecasts Just Became More Bearish On ChemoCentryx, Inc. (NASDAQ:CCXI)
Dec 23ChemoCentryx's avacopan flunks mid-stage study in rare kidney disease study
Dec 21Did The Underlying Business Drive ChemoCentryx's (NASDAQ:CCXI) Lovely 934% Share Price Gain?
Dec 13Are Investors Undervaluing ChemoCentryx, Inc. (NASDAQ:CCXI) By 25%?
Nov 22ChemoCentryx, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 10Revenue & Expenses BreakdownBeta
Revenue & Expenses Breakdown
BetaHow ChemoCentryx makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 22 | 37 | -133 | 97 | 0 |
| 31 Mar 22 | 27 | -141 | 89 | 0 |
| 31 Dec 21 | 32 | -132 | 79 | 0 |
| 30 Sep 21 | 34 | -121 | 68 | 0 |
| 30 Jun 21 | 22 | -123 | 59 | 0 |
| 31 Mar 21 | 69 | -63 | 50 | 0 |
| 31 Dec 20 | 65 | -55 | 42 | 0 |
| 30 Sep 20 | 71 | -41 | 36 | 0 |
| 30 Jun 20 | 76 | -30 | 32 | 0 |
| 31 Mar 20 | 34 | -65 | 27 | 0 |
| 31 Dec 19 | 36 | -55 | 24 | 0 |
| 30 Sep 19 | 35 | -51 | 23 | 0 |
| 30 Jun 19 | 34 | -49 | 22 | 0 |
| 31 Mar 19 | 42 | -40 | 21 | 0 |
| 31 Dec 18 | 43 | -38 | 20 | 0 |
| 30 Sep 18 | 90 | 12 | 19 | 0 |
| 30 Jun 18 | 90 | 17 | 17 | 0 |
| 31 Mar 18 | 84 | 14 | 17 | 0 |
| 31 Dec 17 | 82 | 18 | 17 | 0 |
| 30 Sep 17 | 31 | -29 | 16 | 0 |
| 30 Jun 17 | 26 | -30 | 16 | 0 |
| 31 Mar 17 | 20 | -31 | 15 | 0 |
| 31 Dec 16 | 12 | -40 | 15 | 0 |
| 30 Sep 16 | 7 | -44 | 15 | 0 |
| 30 Jun 16 | 3 | -48 | 15 | 0 |
| 31 Mar 16 | 0 | -51 | 15 | 0 |
Quality Earnings: CCXI is currently unprofitable.
Growing Profit Margin: CCXI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CCXI is unprofitable, and losses have increased over the past 5 years at a rate of 47.2% per year.
Accelerating Growth: Unable to compare CCXI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CCXI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (53%).
Return on Equity
High ROE: CCXI has a negative Return on Equity (-56.27%), as it is currently unprofitable.